NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 194 filers reported holding NEVRO CORP in Q4 2017. The put-call ratio across all filers is 0.98 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $38,351,000 | -2.0% | 480,285 | +6.4% | 0.09% | 0.0% |
| Q1 2018 | $39,120,000 | +32.1% | 451,365 | +5.2% | 0.09% | +34.8% |
| Q4 2017 | $29,611,000 | -25.9% | 428,895 | -2.4% | 0.07% | -25.8% |
| Q3 2017 | $39,935,000 | +12.3% | 439,423 | -8.0% | 0.09% | +14.1% |
| Q2 2017 | $35,563,000 | -8.0% | 477,799 | +15.9% | 0.08% | -4.9% |
| Q1 2017 | $38,637,000 | +10.1% | 412,350 | -14.6% | 0.08% | +6.5% |
| Q4 2016 | $35,078,000 | -22.4% | 482,780 | +11.4% | 0.08% | -18.1% |
| Q3 2016 | $45,232,000 | +41.5% | 433,300 | 0.0% | 0.09% | +40.3% |
| Q2 2016 | $31,960,000 | +34.0% | 433,300 | +2.2% | 0.07% | +48.9% |
| Q1 2016 | $23,843,000 | +35.7% | 423,800 | +62.9% | 0.04% | +60.7% |
| Q4 2015 | $17,566,000 | +202.9% | 260,200 | +108.2% | 0.03% | +180.0% |
| Q3 2015 | $5,799,000 | +50.3% | 125,000 | +74.1% | 0.01% | +66.7% |
| Q2 2015 | $3,859,000 | – | 71,800 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Iron Triangle Partners LP | 562,833 | $40,710,000 | 4.84% |
| Altium Capital Management LP | 77,000 | $5,569,000 | 1.86% |
| PFM Health Sciences, LP | 649,513 | $46,979,000 | 1.76% |
| Rock Springs Capital Management LP | 721,500 | $52,186,000 | 1.31% |
| Integral Health Asset Management, LLC | 50,000 | $3,617,000 | 0.94% |
| Redmile Group, LLC | 411,017 | $29,729,000 | 0.93% |
| K2 PRINCIPAL FUND, L.P. | 114,800 | $8,303,000 | 0.72% |
| Connacht Asset Management LP | 18,762 | $1,357,000 | 0.70% |
| Perceptive Advisors | 477,037 | $34,504,000 | 0.69% |
| ArrowMark Colorado Holdings LLC | 855,439 | $61,874,000 | 0.54% |